Acadia Pharmaceuticals stock hits 52-week low at 18.24 USD
At a glance
- $ACAD today−0.43%last $18.67
- Since Nov 9+13.2%from the first trade after the story
- 52-week range17.7% above low$15.86 – $30.96
- Coverage0 this week1 in 30 days · too few stories to call a pace
Nothing reported about acadia pharmaceuticals across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Policy shifts the whole healthcare aisle; trial data shifts one company. Knowing which kind of story this is helps.
- How the stock is trading: $ACAD -0.43% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
ACADIA Pharmaceuticals ($ACAD) slipped 0.43% to $18.67 in the latest session. Over the past month it is down 5.7%. It now sits 40% under the 52-week high of $30.96 and 18% above the year's low of $15.86. The high sits 95% above the low, a wide range for one year.
How much coverage it is getting
Wook has no other story on ACADIA Pharmaceuticals from the last 30 days, so there is no recent run to compare this one with.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $ACAD page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $ACAD is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 9, 2026. $ACAD has moved +13.15% ($16.50 to $18.67). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
